Equillium, Inc. — Q2 2019 Form 10-Q
Reporting period: Three and six months ended June 30, 2019; balance sheet compared with December 31, 2018. Equillium is a clinical-stage biotechnology company developing itolizumab (EQ001) for severe autoimmune and inflammatory disorders. It has not generated revenue.
Financial performance and position
Amounts below are in millions of dollars, except per-share data.
| Metric | Q2 2019 | Q2 2018 | H1 2019 | H1 2018 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $4.250 | $0.540 | $8.009 | $1.203 |
| General and administrative expense | $2.189 | $0.585 | $4.778 | $0.959 |
| Total operating expenses / operating loss | $6.439 | $1.125 | $12.787 | $2.162 |
| Net loss | $6.069 | $1.765 | $12.019 | $3.342 |
| Basic and diluted net loss per share | $0.35 | $0.16 | $0.69 | $0.31 |
| Operating cash used | Not stated by quarter | $9.220 | $2.058 |
Margins are not meaningful because the company had no revenue. Q2 net loss was partly offset by $0.375 million in interest income; H1 interest income was $0.773 million. There was no interest expense in 2019; 2018 included convertible-note interest expense, and those notes converted to equity in connection with the October 2018 IPO.
| Balance-sheet item | June 30, 2019 | December 31, 2018 |
|---|---|---|
| Cash and cash equivalents | $22.661 | $28.508 |
| Short-term investments | $34.283 | $37.405 |
| Total cash, equivalents and short-term investments | $56.944 | $65.913 |
| Total current assets | $57.796 | $67.099 |
| Total liabilities | $3.825 | $2.228 |
| Stockholders’ equity | $54.063 | $64.935 |
No outstanding debt is reported at June 30, 2019. H1 investing activities provided $3.389 million net, primarily reflecting investment purchases and maturities; financing activities provided no cash. Cash and cash equivalents declined $5.847 million in H1. Accumulated deficit was $27.531 million.
Material changes versus the prior comparable period
- Operating expenses and net loss increased substantially year over year, principally as clinical development advanced and the company expanded staffing and public-company operations. H1 R&D expense increased $6.806 million and G&A expense increased $3.819 million.
- H1 operating cash use increased to $9.220 million from $2.058 million. The company attributed the increase primarily to higher operating expenses.
- Cash, cash equivalents and short-term investments decreased by $8.969 million from year-end 2018. Interest income rose with higher average investment balances compared with 2018.
Outlook, commentary and key risks
- Management said available cash, equivalents and short-term investments were expected to fund currently planned operations for at least 12 months from the filing, while warning that estimates may prove inaccurate and capital could be used sooner. The company said it does not have sufficient funds to complete itolizumab development through regulatory approval and expects to need additional financing.
- Itolizumab is the company’s only product candidate. A Phase 1b/2 aGVHD trial began in Q1 2019, with top-line data from its Phase 1b portion expected in Q1 2020. A Phase 1b proof-of-concept asthma trial began in Australia in June 2019. The FDA accepted the lupus nephritis IND in July 2019; the company planned to start a Phase 1b proof-of-concept trial in the second half of 2019.
- The company expects significant continuing losses and rising R&D costs. Product revenue is not expected for at least several years, if ever; additional equity or debt financing, or collaboration and license arrangements, may be required and could dilute shareholders or limit company rights.
- A material regulatory uncertainty concerns the Cuban origin of intellectual property underlying itolizumab. The company relies on an OFAC general license for import and clinical development and had a pending request for interpretive guidance or specific authorization. If authorization is unavailable, it may be unable to continue development or commercialization.
- Other principal risks include early-stage clinical and regulatory uncertainty, trial enrollment and safety, reliance on Biocon for manufacturing and supply, and dependence on licensed rights. The Biocon agreement includes up to $30 million in regulatory milestones, up to $565 million in sales milestones, and tiered royalties; no milestone or royalty payments had been made or received to date.
- The company reported no legal proceedings. Management concluded disclosure controls were effective at the reasonable-assurance level as of June 30, 2019, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Progress, enrollment, safety findings and timing of results for the aGVHD and asthma trials, and launch timing for the planned lupus nephritis trial.
- Whether the OFAC authorization issue is resolved and whether it permits ongoing development and potential commercialization of itolizumab.
- Actual cash burn, runway assumptions, future financing needs and potential dilution; confirm how the company’s stated runway changes as trials expand.
- Biocon manufacturing and supply continuity, license diligence requirements, and the financial impact of milestone and royalty obligations if development succeeds.
- Potential dilution from equity awards: 1,203,483 stock options were outstanding at June 30, 2019, in addition to other shares reserved for future issuance.